- Home
- MOLN vs SCPH Comparison
MOLN vs SCPH Comparison
Compare MOLN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- SCPH
- Stock Information
- Founded
- MOLN 2004
- SCPH 2013
- Country
- MOLN Switzerland
- SCPH United States
- Employees
- MOLN N/A
- SCPH N/A
- Industry
- MOLN
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- SCPH Health Care
- Exchange
- MOLN Nasdaq
- SCPH Nasdaq
- Market Cap
- MOLN 136.1M
- SCPH 173.6M
- IPO Year
- MOLN 2021
- SCPH 2017
- Fundamental
- Price
- MOLN $3.72
- SCPH $3.97
- Analyst Decision
- MOLN
- SCPH Strong Buy
- Analyst Count
- MOLN 0
- SCPH 3
- Target Price
- MOLN N/A
- SCPH $14.00
- AVG Volume (30 Days)
- MOLN 1.8K
- SCPH 289.9K
- Earning Date
- MOLN 08-25-2025
- SCPH 08-13-2025
- Dividend Yield
- MOLN N/A
- SCPH N/A
- EPS Growth
- MOLN N/A
- SCPH N/A
- EPS
- MOLN N/A
- SCPH N/A
- Revenue
- MOLN $2,525,030.00
- SCPH $41,982,000.00
- Revenue This Year
- MOLN N/A
- SCPH $108.95
- Revenue Next Year
- MOLN $866.67
- SCPH $73.83
- P/E Ratio
- MOLN N/A
- SCPH N/A
- Revenue Growth
- MOLN N/A
- SCPH 138.10
- 52 Week Low
- MOLN $3.36
- SCPH $1.94
- 52 Week High
- MOLN $12.22
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- MOLN 49.47
- SCPH 61.96
- Support Level
- MOLN $3.71
- SCPH $3.77
- Resistance Level
- MOLN $3.89
- SCPH $4.08
- Average True Range (ATR)
- MOLN 0.15
- SCPH 0.17
- MACD
- MOLN 0.01
- SCPH -0.04
- Stochastic Oscillator
- MOLN 41.27
- SCPH 76.92
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.